

OMB APPROVAL	
OMB Number:	3235-0287
Estimated average burden	
hours per response:	0.5

**STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP**

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person* <u>Novartis Bioventures Ltd</u>  (Last) (First) (Middle) <u>C/O NOVARTIS VENTURE FUND</u> <u>FORUM 1 - 1.32, LICHTSTRASSE 35, CH-4056</u>  (Street) <u>BASEL V8 CH-4056</u>  (City) (State) (Zip)	2. Issuer Name and Ticker or Trading Symbol <u>Galera Therapeutics, Inc. [ GRTX ]</u>	5. Relationship of Reporting Person(s) to Issuer (Check all applicable)  Director <input checked="" type="checkbox"/> 10% Owner  Officer (give title below) Other (specify below)
	3. Date of Earliest Transaction (Month/Day/Year) <u>11/12/2019</u>	
	4. If Amendment, Date of Original Filed (Month/Day/Year)	

**Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned**

1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price			
Common Stock	11/12/2019		C		3,293,067 <sup>(1)</sup>	A	(1)	3,293,067	I	See footnote <sup>(2)</sup>
Common Stock	11/12/2019		P		250,000	A	\$12	3,543,067	I	See footnote <sup>(2)</sup>

**Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)**

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares				
Series A Preferred Stock	(1)	11/12/2019		C		9,000,000		(1)	(1)	Common Stock	1,779,864	(1)	0	I	See footnote <sup>(2)</sup>
Series B Preferred Stock	(1)	11/12/2019		C		7,200,000		(1)	(1)	Common Stock	1,423,891	(1)	0	I	See footnote <sup>(2)</sup>
Series C Preferred Stock	(1)	11/12/2019		C		451,609		(1)	(1)	Common Stock	89,311	(1)	0	I	See footnote <sup>(2)</sup>

1. Name and Address of Reporting Person* <u>Novartis Bioventures Ltd</u>  (Last) (First) (Middle) <u>C/O NOVARTIS VENTURE FUND</u> <u>FORUM 1 - 1.32, LICHTSTRASSE 35, CH-4056</u>  (Street) <u>BASEL V8 CH-4056</u>  (City) (State) (Zip)
1. Name and Address of Reporting Person* <u>NOVARTIS AG</u>  (Last) (First) (Middle) <u>LICHTSTRASSE 35, CH-4056</u>  (Street) <u>BASEL V8 CH-4056</u>  (City) (State) (Zip)

**Explanation of Responses:**

1. Upon the closing of the Issuer's initial public offering, each share of preferred stock automatically converted into shares of the Issuer's common stock on a 0.197763-for-one basis.

**Remarks:**

Novartis Bioventures Ltd., By: /s/ Bart Dzikowski, Name: Bart Dzikowski, Title: Secretary of the Board, By: /s/ Stephan Sandmeier, Name: Stephan Sandmeier, Title: Authorized Signatory, 11/12/2019  
Novartis AG, By: /s/ Bart Dzikowski, Name: Bart Dzikowski, Title: Attorney-in-Fact, By: /s/ Stephan Sandmeier, Name: Stephan Sandmeier, Title: Attorney-in-Fact, 11/12/2019  
\*\* Signature of Reporting Person      Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

\* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

\*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

**Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.**